Overview
LUCD market data
Price History
LUCD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -876.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.86 – $1.63 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $195.9M · P/B 13.07 · P/S 38.17.
Company News
Lucid Diagnostics Q2 2026 Earnings Call: Complete TranscriptBenzinga · Aug 13, 2026, 3:11 PM
8-K filing — Lucid Diagnostics Inc. (LUCD)SEC EDGAR · Aug 13, 2026, 12:23 PM
Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M EstimateBenzinga · Aug 13, 2026, 11:46 AM
Lucid Diagnostics Announces Concert Issues Positive Coverage Policy Effective July 2026 For EsoGuard Esophageal DNA Test Across Its Client Health PlansBenzinga · Aug 5, 2026, 12:48 PM
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull CaseBenzinga · Jun 8, 2026, 3:30 PM
Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2Benzinga · May 15, 2026, 7:55 PM
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price TargetBenzinga · May 15, 2026, 11:45 AM